Basel researchers develop innovative origami-inspired heart patch
Swiss scientists create groundbreaking medical device using paper-based technology to treat heart attack patients
Swiss scientists create groundbreaking medical device using paper-based technology to treat heart attack patients

"The heart has a very limited capacity for repair and regeneration. If not treated properly, this damage can worsen over time and lead to heart failure."
"Thatâs why itâs essential to restore cardiac function. A personâs heart may still pump after a heart attack, but if it doesnât function optimally, it can lead to serious health problems."
Titanium plates and electronic chips are yesterday's news; the future of cardiac medicine is being folded from paper in Basel. In a stunning display of cross-disciplinary innovation, a coalition of Swiss researchers has unveiled a biomedical breakthrough that merges the ancient art of Japanese origami with cutting-edge nanotechnology. This is not science fictionâit is the result of a powerhouse collaboration between the University of Basel, FHNW, the Swiss Nanoscience Institute (SNI), and OMYA International AG.
The team has successfully developed a prototype heart patch designed to mitigate the devastating consequences of myocardial infarction. Published this March in the prestigious ACS Biomaterials Science and Engineering, their work represents a paradigm shift in how we approach organ regeneration. By utilizing cell-loaded paper technology, these scientists are moving beyond simple mechanical fixes to create living, breathing solutions for damaged hearts. This bold step asserts Basel's dominance as a global hub for life sciences, proving once again that Swiss innovation knows no bounds.
Heart conditions remain the undisputed leading cause of death in Switzerland, a statistic that casts a long shadow over the nation's health landscape. When a patient suffers a heart attack, the clock ticks mercilessly. Ischaemiaâthe blockage of oxygen-rich bloodâstarves the heart tissue, causing irreversible cell death. While immediate survival rates have improved, the aftermath is often a slow, debilitating decline into heart failure.
"The heart has a very limited capacity for repair and regeneration," asserts Anna Marsano of the Department of Biomedicine at the University of Basel. Her warning is stark: without intervention, the damage compounds. Current treatments, such as stents or drug therapies, often act as stopgaps rather than cures. This new origami patch aims to change the narrative entirely. By replacing dead cells and restoring the heart's pumping efficiency, this device confronts the crisis head-on, offering a glimmer of hope where previously there was only damage control.
Nature meets nanotechnology in a feat of engineering brilliance. To mimic the complex, rhythmic contractions of the human heart, researchers turned to a surprising material: pure cellulose paper. However, a flat sheet was insufficient. The team meticulously folded these cellulose sheets into miniature accordion-like structures, creating a scaffold that can expand and contract in perfect unison with the heart muscle.
Maurizio Gullo of FHNW emphasizes the precision required: "We explored various approaches and found that the folding pattern was essential." These sheets are coated with a specialized gelatine and populated with lab-grown vascular and cardiac cells. The result is a device that physically behaves like the myocardium. Currently, the prototype features a single layer of vascular and cardiac cells, yet it already demonstrates the ability to stretch and contractâa critical proof of concept that validates the origami approach.
The journey from a petri dish in Basel to a patient's chest is fraught with challenges, but the roadmap is clear and ambitious. While the current results are confined to in vitro laboratory experiments, the trajectory is set for rapid advancement. "The next step will be to add additional layers and make the patch fully functional," explains researcher Antonio Sileo. The team is not resting on its laurels; they are already eyeing the next critical milestones.
The testing phase will escalate from small animal models, such as mice, to larger mammals like pigs, before finally reaching clinical trials on humans. This rigorous process ensures safety and efficacy, but the urgency is palpable. With heart failure continuing to claim lives across the cantons, the pressure is on. This project is more than just an experiment; it is a race against time to deliver a tool that could save thousands, transforming a researcherâs pioneering idea into a lifeline in a doctorâs hands.